Erin Furr Stimming, MD, FAAN, FANA, McGovern Medical School, UTHealth, Houston, TX, discusses the ongoing disease-modifying trials for Huntington’s disease (HD). While it may not be possible to silence or eliminate the Huntington gene, there is optimism surrounding the ability to modify huntingtin. The HD community faced significant challenges due to negative trial outcomes, but valuable insights have been gained from those trials. Technological advances have propelled research forward, resulting in the study of orally available small molecules and a micro RNA interference molecule delivered through a viral vector. Additionally, Dr Furr Stimming mentions the identification of other genes and genetic modifiers influencing the age of motor onset and progression rate, with plans for further evaluation. Overall, there is optimism and hope for positive results from the disease-modifying trials. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
